TrivarX Advances Stabl-Im Toward First Human Study, Targets Enrolment Next Year
TRI: $0.009 +12.50% · MC: $12M
TrivarX says it has progressed preparations for Stabl-Im’s planned Phase 1 healthy-volunteer study, including starting pre-clinical work, receiving investigational product and appointing Syntro Health after quarter-end to prepare and test trial supplies. First participant enrolment is targeted for early 2027, with initial study results anticipated later that year, subject to remaining requirements; pre-clinical results are expected in the current quarter. The company reported approximately A$2 million in cash at quarter-end.

Comments